RespireRx Pharmaceuticals IncOver The Counter Market:RSPI
- LAST PRICE0.0008
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0008
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
RespireRx Pharmaceuticals Inc | 292.3K | -0.1x | --- |
Myrexis Inc | 241.4K | 0.0x | --- |
Propanc Biopharma Inc | 237.0K | 0.0x | --- |
GlobeStar Therapeutics Corp | 348.9K | -0.1x | --- |
TC Biopharm (Holdings) PLC | 329.7K | 0.0x | --- |
LadRx Corp | 396.1K | -0.1x | --- |
Company Information
RespireRx Pharmaceuticals Inc. develops treatments to combat disorders caused by disruption of neuronal signaling. The Company is developing treatment options that address conditions, such as obstructive sleep apnea (OSA), attention deficit hyperactivity disorder, epilepsy, acute and chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect millions of people, as well as certain orphan disorders such as GRIA. It also considers developing treatment options for other conditions based on results of preclinical and clinical studies to date. The Company has two business units. ResolutionRx unit holds its pharmaceutical cannabinoids platform, and is developing compounds that target the body’s endocannabinoid system, and in particular, the re-purposing of dronabinol for the treatment of OSA. EndeavourRx is its neuromodulators platform, which is made up of two programs: AMPAkines program and GABAkines program.
Contact Information
- Headquarters
- 126 Valley Rd Ste CGLEN ROCK, NJ, United States 07452-1796
- Phone
- 201-444-4947
- Fax
- 302-652-6760
Executives
- Executive Chairman of the Board, Interim President, Interim Chief Executive Officer, Chief Scientific Officer
- Arnold Lippa
- Chief Financial Officer, Senior Vice President, Treasurer, Secretary, Director
- Jeff Margolis
- Senior Vice President - Pre-Clinical Product Development
- David Dickason
- Senior Vice President - Research and Development
- Richard Purcell
- Director
- Dariusz Nasiek
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $292.3K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 365.4M |
RespireRx Pharmaceuticals Inc does not pay a dividend. | |
Beta | 0.62 |
EPS | $-0.01 |
Book Value | $-0.09 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
